The Draft Project Plan on WP5-SA6 ‘Rapid Relative Effectiveness Assessment of new pharmaceuticals for the treatment of chronic hepatitis C’ was open to public consultation between June 23, 2015 and July 7, 2015.
The development of the methodological guidelines was included in the work plan of the EUnetHTA JA in years 2009-2012, and is one of the objectives of the EUnetHTA JA2. The primary aim of the guidelines is to help the assessors of evidence to process, analyse and interpret the data.
A joint assessment is structured information for rapid or full HTAs which is the output of joint production in which 2 or more countries and/or organisations work together to prepare shared products or agreed outcomes*.
The EUnetHTA Stakeholder Forum is formed to ensure a transparent engagement with a broad range of stakeholders and is comprised of representatives from patient and healthcare consumer organisations, healthcare providers, payers (statutory health insurance) and the industry. The Stakeholder Forum's composition aims at ensuring broad and balanced representation of stakeholder interests.
Organisations representing interests of four stakeholder groups – patients/consumers, industry, payers (statutory health insurance) and healthcare providers can participate via the EUnetHTA Stakeholder Forum.
Public Consultations are held regularly as a form of soliciting public input on the draft documents produced by EUnetHTA within the framework of implementing the EUnetHTA Joint Action 2 grant agreement and 3-year EUnetHTA Joint Action 2 Work Plan.
Announcements of the public consultations are made in the "News" section of this website.
The full list of public consultations (ongoing or closed) is available in the "Get involved" section of this website